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High systolic blood pressure caused by endothelial dysfunction is a comorbidity of metabolic syndrome
that is mediated by local inﬂammatory signals. Insulin-induced vasorelaxation due to endothelial nitric
oxide synthase (eNOS) activation is highly dependent on the activation of the upstream insulin-
stimulated serine/threonine kinase (AKT) and is severely impaired in obese, hypertensive rodents and
humans. Neutralisation of circulating tumor necrosis factor-a (TNFa) with inﬂiximab improves glucose
homeostasis, but the consequences of this pharmacological strategy on systolic blood pressure and
eNOS activation are unknown. To address this issue, we assessed the temporal changes in the systolic
pressure of spontaneously hypertensive rats (SHR) treated with inﬂiximab. We also assessed the
activation of critical proteins that mediate insulin activity and TNFa-mediated insulin resistance in the
aorta and cardiac left ventricle. Our data demonstrate that inﬂiximab prevents the upregulation of both
systolic pressure and left ventricle hypertrophy in SHR. These effects paralleled an increase in
AKT/eNOS phosphorylation and a reduction in the phosphorylation of inhibitor of nuclear factor-kB
(Ikb) and c-Jun N-terminal kinase (JNK) in the aorta. Overall, our study revealed the cardiovascular
beneﬁts of inﬂiximab in SHR. In addition, the present ﬁndings further suggested that the reduction of
systolic pressure and left ventricle hypertrophy by inﬂiximab are secondary effects to the reduction of
endothelial inﬂammation and the recovery of AKT/eNOS pathway activation.
& 2012 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
Recent studies have demonstrated that insulin resistance,
endothelial dysfunction and vascular inﬂammation play impor-
tant roles in the aetiology of hypertension. Insulin resistance, a
key event in the pathophysiology of type 2 diabetes mellitus, is
characterised by an inappropriate response of peripheral organs
to insulin (DeFronzo, 2010). The disruption of intracellular insulin
signal transmission is related to insulin resistance in such way
that several possible molecular mechanisms have been described
to impair insulin-induced glucose uptake by skeletal muscles and
adipose tissue in diabetic patients (Cnop et al., 2011).
In addition to its role in glucose homeostasis, insulin is an
important mediator of vasorelaxation through a mechanism that
involves endothelium-dependent nitric oxide (NO) production
(Scherrer et al., 1994). Insulin-mediated NO generation by
endothelial cells results from the upstream activation of theax: þ55 19 3289 2968.
r).
ier OA license. insulin-stimulated serine/threonine kinase (AKT) pathway (Zeng
et al., 2000). AKT leads to the direct activation of endothelial
NO synthase (eNOS) by phosphorylating serine 1177 of eNOS
(Dimmeler et al., 1999).
Endothelial dysfunction is thought to play an important role in
the genesis of hypertension by increasing vascular tone and blood
pressure (Desjardins and Balligand, 2006). Therefore, endothelial
insulin resistance and the subsequent impairment of insulin-
induced vasorelaxation through stimulation of NO synthesis are
being investigated as relevant mechanisms for diabetes-related
vascular dysfunction (Lee et al., 2009; Yang et al., 2009). Impor-
tantly, activation of the insulin-induced AKT/eNOS pathway is
impaired in the aorta of spontaneous hypertensive rats (SHR)
(Zecchin et al., 2003).
Tumor necrosis factor-a (TNFa) is an inﬂammatory cytokine
produced in rats that are both insulin resistant and hypertensive
(Espinola-Klein et al., 2011). Several studies have indicated that
TNFa action is a key factor in insulin resistance in peripheral
insulin-sensitive tissues and endothelial dysfunction (de Alvaro
et al., 2004). Recent studies have reported that inﬂiximab, a
TNFa-neutralising antibody, effectively restores AKT activity in
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thus improving glucose homeostasis (Arau´jo et al., 2007; Barbuio
et al., 2007).
The present study was designed to assess the putative effects
of inﬂiximab treatment on AKT and eNOS phosphorylation in the
aortas of SHR. In addition, we investigated the effects of inﬂiximab
on the systolic blood pressure levels and left ventricle hypertrophy
that are characteristic of this animal model of hypertension.2. Materials and methods
2.1. Experimental design
Male Wistar Kyoto rats (WKY) and spontaneous hypertensive
rats (SHR) weighing 200–250 g were obtained from the Central
Animal House Services (CEMIB) of the State University of Campinas.
These animals were divided into six groups (n¼10): WKY receiving
water as vehicle (WKYþveh), WKY receiving 1.5 mg/kg/week inﬂix-
imab (WKYþ inﬂix 1.5), WKY receiving 6 mg/kg/week inﬂiximab
(WKYþ inﬂix 6), SHR receiving water as vehicle (SHRþveh), SHR
receiving 1.5 mg/kg/week inﬂiximab (SHRþ inﬂix 1.5) and SHR
receiving 6 mg/kg/week inﬂiximab (SHRþ inﬂix 6). s.c. injections of
inﬂiximab or vehicle were performed once a week beginning when
the animals were 8 weeks old. All animals were kept on a strict
light/dark-cycle (12-h light, 12-h dark) with free access to food and
water. All of the experiments described in this manuscript were
approved by the Committee for Ethics in Animal Experimentation
(CEEA) located in the Institute of Biology of the State University of
Campinas. The CEEA guidelines are in accordance with the NIH
Guide for the Care and Use of Laboratory Animals and with the
ethical guidelines established by the Brazilian College for Animal
Experimentation (COBEA).
2.2. Insulin tolerance test (ITT) and glucose tolerance test (GTT)
The animals were fasted for 12 h before the ITT and GTT. The
ITT was performed by injecting insulin (2 IU/kg) i.p., and blood
samples were collected from the tail at 0 min, 5 min, 10 min,
15 min, 20 min, 25 min and 30 min for the determination of blood
glucose levels. The constant rate for glucose disappearance (KITT)
was calculated using the following formula: KITT¼0.693/half-
time. The glucose half-time of glucose decay was calculated from
the slope of the least-square analysis of the blood glucose
concentrations during the linear decay phase.
The GTT was performed by i.p. glucose injection (2 g/kg of a
20% solution of D-glucose). Blood samples were collected from the
tail at 0 min, 10 min, 15 min, 30 min, 60 min and 120 min for the
determination of blood glucose levels. The area under the curve
(AUC) of glycaemia vs. time was calculated above each individual
baseline (basal glycaemia) to estimate glucose tolerance.
For both the GTT and ITT, blood glucose was measured using
an Accu-Chek Active glucometer and the appropriate test strips
(Roche Diagnostics, Basel, Switzerland).
2.3. Non-invasive (tail-cuff) blood pressure and body weight
measurements
Blood pressure was assessed using the tail-cuff method with a
noninvasive blood pressure system (CODAHT41EA, Kent Scientiﬁc
Corporation, Torrington, Connecticut, USA). Systolic blood pres-
sure levels of the WKY and SHR treated with either vehicle or
inﬂiximab were measured twice a week throughout the study,
and the mean of these two measurements was determined.
The rats were placed in a holder for three consecutive days
(15 min per day) prior to beginning blood pressure measurements.On the day of blood pressure measurements, the rats were conﬁned
in small, dark holders for 10 min to 15 min prior to obtaining
pressure measurements. Before and during these measurements,
the holders were placed over warming pads (Far Infrared Stasis
Technology, Kent Scientiﬁc Corporation, Connecticut, USA). Body
temperature and heart rate were monitored throughout the blood
pressure measurements, and no changes were observed in these
parameters during the procedure.
2.4. Echocardiography
After 8 weeks of treatment with inﬂiximab or vehicle, the
rats were subjected to a transthoracic echocardiographic study
under anaesthesia with intraperitoneal injection of ketamine
HCl (10 mg/kg) and xylazine (10 mg/kg). Two-dimensional and
M-mode echocardiogram images were obtained at the papillary
muscle level using an echocardiographic system equipped with an
11.5-MHz phased array transducer. The left ventricular volume and
ejection fraction were calculated using the single-plane prolate
ellipsoid geometric model from the parasternal long-axis view.
Two independent, blinded investigators performed echocardio-
graphic studies with a commercially available Siemens Acuson
CV70 echo-scanner (Siemens Aktiengesellschaft—Munich, Bavaria,
Germany) with a mutifrequency sector transducer (2–4 MHz) placed
on the shaved left hemithorax of the rats. The M-mode measure-
ments included end-diastolic septal thickness, end-diastolic poster-
ior thickness, left-ventricular end-systolic and end-diastolic
diameters, left ventricular ejection fraction, left ventricular mass,
left ventricular mass index and relative wall thickness. The heart
rate was also recorded.
The left ventricular ejection fraction and left ventricular mass
were calculated as follows: ([{left-ventricular end diastolic diameter3
– left-ventricular end systolic diameter3}/left-ventricular end systolic
diameter3]100) and 0.8 {1.04 [(interventricular septal wall
thicknessþposterior wall thicknessþ left-ventricular end diastolic
diameter)3 – (left-ventricular end diastolic diameter3)]}þ0.6, respec-
tively. The mass values were obtained in grams. Digital data of 10
consecutive heart cycles were recorded and transferred to a personal
computer work-station for off-line analysis (Brown et al., 2002;
Watson et al., 2004). The left ventricular mass index was obtained
by normalising the left ventricular mass to the body weight.
2.5. Histological analysis
After 8 weeks of treatment, the rats were euthanised and the
heart was removed and ﬁxed in 10% formalin for 24 h. Subse-
quently, the atria were removed, and the left ventricle was care-
fully separated from the right ventricle and cut into four equal
rings perpendicular to the long axis of the heart. The tissue
samples were subsequently processed using routine histological
methods. Brieﬂy, tissues were sectioned (5 mm), stained with
hematoxylin–eosin and analysed by light microscopy. For each
rat (n¼5), twenty ﬁelds of view of each section were randomly
studied by light microscopy (Leica Q500 iW Leica DMLS, Leica
Imaging Systems, Cambridge, UK).
All ﬁelds of view (1600 per group) were captured with a digital
camera to produce ampliﬁed images (40 ), which were analysed
with commercial software (Quantimet 500, Cambridge Instru-
ments, Cambridge, UK). The heart samples were coded and then
assessed by two independent, blinded observers.
2.6. Protein extraction and western blot
Rats were anaesthetised with sodium thiopental (100 mg/kg
body wt). Once, anaesthesia was ascertained by the loss of pedal
reﬂex, the thoracic cavity was opened and the thoracic aorta was
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dodecyl sulphate, 100 mM Tris (pH 7.4), 10 mM EDTA, 10 mM
sodium pyrophosphate, 100 mM sodium ﬂuoride, 10 mM sodium
vanadate) with a Polytron PTA 20S generator (model PT 10/35;
Brinkmann Instruments, Inc., Westbury, NY) operated at max-
imum speed for 30 s. The left ventricle was also removed and
processed for protein extraction. The extracts were processed,
subjected to SDS-PAGE (10% bis-acrylamide) and electrotrans-
ferred to a nitrocellulose membrane as previously described
(Caperuto et al., 2008). Nonspeciﬁc protein binding to nitrocellu-
lose was reduced by preincubating the membranes overnight
at 4 1C in blocking buffer (5% non-fat dried milk, 10 mm Tris,
150 mm NaCl, and 0.02% Tween-20). After blocking, the nitrocel-
lulose membranes were incubated with primary antibodies.
Anti-phospho-AKT (Ser 473), anti-Ikb, anti-AKT 1/2/3, anti-phospho-
JNK (Thr 183/Tyr 185) and anti-TNFa were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phospho-Ikb (Ser
32) was purchased from Cell Signalling Technology (Beverly, MA,
USA). Anti-phospho-eNOS (Ser 1177), anti-eNOS and anti-b-actin
were obtained from Millipore. Bound antibodies were detected
with horseradish peroxidase-conjugated anti-IgG and visualised
by chemiluminescence with X-ray-sensitive ﬁlms. Band intensi-
ties were quantiﬁed from the developed autoradiographs using
the Scion Image program.
2.7. Caspase-3 processing
Caspase-3 processing was determined after detection of
caspase-3 and Pro-caspase-3 by western blotting with a poly-
clonal antibody (Cat. No. sc1225; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). After optical densitometry analysis, the values of
caspase-3 were normalised to those of Pro-caspase-3.
2.8. Statistical analyses
The results are presented as the mean7S.E.M. Comparisons
were performed using a one-way ANOVA, with Tukey–Kramer
post-test (INStat; Graph Pad Software, Inc., San Diego, CA) and the
unpaired Student’s t test when appropriate. The level of signiﬁ-
cance was set at Po0.05.3. Results
3.1. Inﬂiximab increases glucose tolerance and insulin sensitivity
and decreases systolic pressure in SHR
Initially, we wanted to determine whether inﬂiximab would
modulate glucose tolerance in WKY and SHR rats (Fig. 1A and B).
By analysing the AUC, we found that rats in the SHRþveh group
displayed no changes in glucose tolerance compared to those of
the WKYþveh group. Inﬂiximab treatment improved glucose
tolerance exclusively in the SHR independent of the dose (values
of SHRþ inﬂix 1.5 and SHRþ inﬂix 6 were 51% and 57% lower than
that of SHRþveh, respectively; Po0.05) (Fig. 1C). Fasting glycae-
mia was unaltered by inﬂiximab treatment in both WKY and SHR
(Fig. 1D). In agreement with previous data (Zecchin et al., 2003),
we found that insulin sensitivity was decreased in rats in the
SHRþveh group compared to those of the WKYþveh group
(to 47% of WKYþveh values; Po0.05). Inﬂiximab treatment
increased insulin sensitivity in rats of the SHRþ inﬂix 6 group
compared to those of the SHRþveh group (to 249% of SHRþveh
values; Po0.05) (Fig. 1E).
No changes in body weight were detected during the treat-
ment period, resulting in a similar ﬁnal body weight among the
groups (Fig. 2A and B). Inﬂiximab did not alter systolic bloodpressure in WKY (Fig. 2C). In contrast, inﬂiximab treatment
induced a progressive decrease in systolic blood pressure in
SHR. This decrease in systolic blood pressure was detected as
early as the end of the sixth week of treatment. Thus, at the end of
the sixth week, systolic blood pressure was signiﬁcantly reduced
in the rats in the SHRþ inﬂix 1.5 and SHRþ inﬂix 6 groups
compared with those in the SHRþveh group (22% and 21% lower
than SHRþveh values, respectively; Po0.05). The reduction in
systolic pressure induced by inﬂiximab was detected up to the
eighth week of treatment in the SHRþ inﬂix 1.5 and SHRþ inﬂix
6 groups (41% lower than SHRþveh values; Po0.05) (Fig. 2D).
3.2. Inﬂiximab increases AKT and eNOS phosphorylation in the aorta
of SHR
Reduced activation of the AKT/eNOS pathway is suggested to
contribute to increased blood pressure values in SHR (Zecchin et al.,
2003). Thus, the next step of our investigation was to assess whether
inﬂiximab would modulate AKT/eNOS pathway in the aorta of SHR.
We found that the aortas of the SHRþveh rats displayed reduced
levels of AKT phosphorylation compared to those of WKYþveh rats
(63% lower than WKYþveh values Po0.05). Inﬂiximab treatment
increased the level of AKT phosphorylation compared to that
observed in the SHRþveh group (values of SHRþ inﬂix 1.5 and
SHRþ inﬂix 6 were 97% and 86% higher than those of SHRþveh,
respectively; Po0.05). AKT phosphorylation in the aortas of WKY
was not modulated by inﬂiximab (Fig. 3B). The total AKT levels were
unaltered among the groups and were used to normalise the values
of phosphorylated AKT.
In addition, our data show that eNOS phosphorylation is
reduced in the aortas of SHRþveh rats (71% lower than WKYþ
veh values; Po0.05). Treatment with inﬂiximab increased the
levels of eNOS phosphorylation compared to the levels observed
in rats in the SHRþveh group (values of SHRþ inﬂix 1.5 and
SHRþ inﬂix 6 were 171% and 236% higher, respectively, than
those of SHRþveh; Po0.05). Phosphorylation of eNOS in the
aortas of WKY was not affected by inﬂiximab (Fig. 3D). The total
eNOS levels were unaltered among the groups and were used to
normalise the values of phosphorylated eNOS.
3.3. Inﬂiximab reduces TNFa expression and activity of
inﬂammatory pathways in the aorta of SHR
Increased endothelial JNK and NFkB pathways activation is
reported to occur in SHR (Sugita et al., 2004; Sanz-Rosa et al.,
2005). The increased activity of these pathways prompted us to
evaluate whether the inﬂiximab-induced changes in AKT/eNOS
pathway were associated with modulation of inﬂammatory
pathways. Our data demonstrated that JNK phosphorylation
was 143% higher in the aortas of rats in the SHRþveh group
compared to the aortas of rats in the WKYþveh group (Po0.05).
Inﬂiximab reduced JNK phosphorylation in the aortas of rats in
the SHRþ inﬂix 1.5 and SHRþ inﬂix 6 groups (to 48% and 22% of
the SHRþveh values, respectively; Po0.05). Interestingly, the
higher dose of inﬂiximab promoted an increase in JNK phosphor-
ylation in the aortas of WKY (134% higher than WKYþveh;
Po0.05) (Fig. 3F). The phosphorylation levels of JNK were
normalised to those of b-actin.
The phosphorylation levels of Ikb, a direct target of IkK,
were not signiﬁcantly different when comparing the aortas of
WKYþveh rats to those of SHRþveh rats. Treatment with
inﬂiximab reduced the phosphorylation of Ikb in the aortas of
rats in the SHRþ inﬂix 1.5 and SHRþ inﬂix 6 groups (to 48% and
42% of SHRþveh values, respectively; Po0.05) but did not alter
Ikb phosphorylation in the aortas of WKY (Fig. 3E). Total Ikb
levels were used to normalise the values of phosphorylated Ikb.
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Fig. 1. Glucose tolerance, insulin sensitivity and fasting glycaemia in WKY and SHR treated with inﬂiximab. WKY and SHR treated with vehicle or inﬂiximab for
8 weeks were subjected to a glucose tolerance test ((A) and (B), respectively). The AUC of each animal was calculated using the individual baseline (C). Twelve-hour fasting
glycaemia was determined prior to glucose challenge (D). To estimate insulin sensitivity, KITT was calculated using glycaemia values acquired during the ITT (E). The dotted
line with open circles represents the WKYþveh group, the solid line with open circles represents the WKYþ inﬂix 3 group, the solid line with closed circles represents the
WKYþ inﬂix 6 group, the dotted line with open squares represents the SHRþveh group, the solid line with open squares represents the SHRþ inﬂix 3 group and the solid
line with closed squares represents the SHRþ inﬂix 6 group. The data are presented as the mean7S.E.M. nPo0.05 vs. SHRþveh; #Po0.05 vs. WKYþveh.
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pared to that of the WKYþveh group. In agreement with the
reductions in JNK and Ikb phosphorylation, we also found that
inﬂiximab reduced TNFa expression in the aortas of SHR (values of
TNFa levels in SHRþ inﬂix 1.5 and SHRþ inﬂix 6 were 66% and 96%
lower, respectively, than those of SHRþveh; Po0.05). Similarly,
inﬂiximab reduced TNFa expression in the aortas of WKY (values of
WKYþ inﬂix 1.5 and WKYþ inﬂix 6 were 22% and 39% lower,
respectively, than those of WKYþveh; Po0.05) (Fig. 3C). The values
for TNFa expression were normalised to those of b-actin.
3.4. Inﬂiximab reduces cardiac hypertrophy and does not interfere
with ventricular function in SHR
To assess if the reduction in blood pressure following inﬂix-
imab treatment is correlated with an impairment of ventricularfunction caused by inﬂiximab (Anker and Coats, 2002), we next
investigated the cardiac tissue of WKY and SHR treated with
either vehicle or inﬂiximab. Echocardiography of untreated and
inﬂiximab-treated WKY and SHR rats (8 weeks of treatment)
revealed no differences in heart rate, ejection fraction and left-
ventricular end-systolic and end-diastolic diameters at different
inﬂiximab doses. Although its effect was not dose dependent,
inﬂiximab reduced end-diastolic septal wall thickness, end-
diastolic posterior wall thickness, relative wall thickness, left
ventricle mass and left ventricle mass index in SHR. Consistent
with this echocardiographic ﬁnding, histometric analysis showed
that inﬂiximab reduced the diameters of cardiomyocytes in SHR.
We also found that left ventricle mass, left ventricle mass index,
relative wall thickness and cardiomyocyte diameters were
increased in rats of the SHRþveh group compared to those of
the WKYþveh group (Table 1).
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Fig. 2. Body weight and systolic blood pressure in WKY and SHR during inﬂiximab treatment. The body weights of WKY and SHR treated with vehicle or inﬂiximab
((A) and (B), respectively) and the systolic blood pressure ((C) and (D), respectively) were measured weekly after the ﬁrst week until the end of the eighth week of
treatment. The dotted line with open circles represents the WKYþveh group, the solid line with open circles represents the WKYþ inﬂix 3 group, the solid line with closed
circles represents the WKYþ inﬂix 6 group, the dotted line with open squares represents the SHRþveh group, the solid line with open squares represents the SHRþ inﬂix
3 group and the solid line with closed squares represents the SHRþ inﬂix 6 group. The data are presented as the mean7S.E.M. #Po0.05 vs. the same group at the ﬁrst
week; nPo0.05 vs. SHRþveh at the same time point.
A.G. Filho et al. / European Journal of Pharmacology 700 (2013) 201–209 2053.5. Inﬂiximab reduces AKT phosphorylation and caspase-3
processing in the left ventricle of SHR
Our analysis of cardiac parameters revealed that JNK phos-
phorylation, although elevated in the left ventricle of SHRþveh
rats (89% higher than in WKYþveh; Po0.05), was not modulated
by inﬂiximab in the WKY and SHR groups (Fig. 4B). Cardiac TNFa
expression was similar in the WKYþveh and SHRþveh groups
and was not modulated by inﬂiximab in the SHR group. However,
higher doses of inﬂiximab stimulated TNFa expression in the left
ventricle (71% higher than WKYþveh; Po0.05) (Fig. 4C).
Ikb phosphorylation was increased in the left ventricle of SHRþ
veh rats (412% higher than in WKYþveh; Po0.05). Treatment with
inﬂiximab did not alter Ikb phosphorylation in WKY but reduced
this phosphorylation in SHR (the values in SHRþ inﬂix 1.5 and
SHRþ inﬂix 6 were 47% and 71% lower, respectively, than in
SHRþveh; Po0.05) (Fig. 4D).
AKT phosphorylation was increased in the left ventricle of
SHRþveh rats (15% higher than in WKYþveh; Po0.05). Inﬂix-
imab treatment, however, reduced AKT phosphorylation in the
left ventricles of SHR (values in SHRþ inﬂix 1.5 and SHRþ inﬂix
6 were 21% and 42% lower than in SHRþveh, respectively;
Po0.05) but not in those of WKY (Fig. 4E).
To assess putative changes in cell death within the cardiac
tissue, we analysed caspase-3 processing, a hallmark of cellular
apoptosis. Our data show that caspase-3 processing was reduced
in the left ventricles of rats in the SHRþ inﬂix 6 group (to 31% of
SHRþveh values; Po0.05) (Supplementary Fig. 1).4. Discussion
The present investigation revealed that an 8-week treatment
with inﬂiximab was able to reduce systolic pressure levels andleft ventricular hypertrophy in spontaneously hypertensive rats.
This is the ﬁrst demonstration that the use of inﬂiximab, often
administered to normotensive patients, can result in cardio-
vascular beneﬁts in a rodent model of spontaneous hypertension.
The mechanism that we suggest to explain this effect was based
on previous reports regarding the use of inﬂiximab in obese/
hypertensive patients. The use of inﬂiximab in subjects with
metabolic syndrome results in a potentiation of the vasodilatation
induced by insulin during a hyperinsulinemic/euglycaemic clamp
(Tesauro et al., 2008). Importantly, these results obtained by
Tesauro et al. (2008) demonstrated that the effect of inﬂiximab
was dependent on NO synthesis. In addition, sera that were
obtained from patients with Crohn’s disease who were treated
with inﬂiximab induced increased eNOS expression when added
to human umbilical vein endothelial cells (Altorjay et al., 2011).
Our data also show that inﬂiximab did not alter blood pressure
values in normotensive WKY rats.
Based on these previous studies of inﬂiximab, we sought
to correlate the improvement in systolic pressure induced by
inﬂiximab in SHR with secondary changes in pathways involved
in vascular relaxation. Phosphorylation of eNOS at serine 1177
facilitates NO production by this enzyme (Dimmeler et al., 1999).
Notably, a reduction in eNOS activity is known to be involved in
the hypertensive state of SHR (Chou et al., 1998). Consistent with
the published information, our data show that eNOS phosphor-
ylation is reduced in the aorta of SHR. Moreover, we found that
inﬂiximab increased eNOS phosphorylation in the aorta of SHR.
Reduced eNOS and AKT phosphorylation are simultaneously
present in the aorta of SHR (Zecchin et al., 2003). Because AKT, a
canonical substrate of insulin signalling, is an important upstream
effector that targets eNOS serine phosphorylation (Dimmeler
et al., 1999) we next assessed whether changes in AKT phosphor-
ylation would correlate with the effects of inﬂiximab on eNOS
phosphorylation. Our data revealed that AKT phosphorylation
Fig. 3. AKT/eNOS activation and inﬂammatory pathways in the aorta of WKY and SHR treated with inﬂiximab. The aortas were removed from WKY and SHR treated
with either vehicle or inﬂiximab for 8 weeks, and samples were prepared for western blot detection of phospho-AKT, AKT, phospho-eNOS, eNOS, TNFa, phospho-Ikb, Ikb,
phospho-JNK and b-actin (A). Values of phospho-AKT were normalised to total AKT (B). Values of TNFa were normalised to b-actin (C). Values of phospho-eNOS were
normalised to total eNOS (D). Values of phospho-Ikb were normalised to total Ikb (E). Values of phospho-JNK were normalised to b-actin (F). The data are presented as the
mean7S.E.M. nPo0.05 vs. WKYþveh; #Po0.05 vs. SHRþveh.
A.G. Filho et al. / European Journal of Pharmacology 700 (2013) 201–209206was reduced in the aorta of vehicle-treated SHR but was increased
after inﬂiximab treatment. These data are in accordance with
previous publications that demonstrated that inﬂiximab increases
AKT phosphorylation in insulin-sensitive peripheral tissues (Arau´jo
et al., 2007; Barbuio et al., 2007).
Published data support the hypothesis that inﬂiximab-induced
upregulation of the AKT/eNOS pathway is likely due to the neutralis-
ing properties upon circulating TNFa. In support of this hypothesis,TNFa signalling through the NF-kB pathway was described to
contribute to endothelial dysfunction in obese mice (Yang et al.,
2009, AJP). Moreover, TNFa production by small arteries is able to
mediate a reduction in NO-dependent relaxation (Virdis et al., 2011).
After establishing that the effect of inﬂiximab on SHR corre-
lates with upregulation of the AKT/eNOS pathway in the aorta and
with a reduction of systolic blood pressure, we analysed putative
changes in TNFa signalling that are associated with abrogation
Table 1
Echocardiographic parameters and cardiomyocyte diameter in WKY and SHR after 8 weeks of treatment either with vehicle or inﬂiximab.
WKYþveh WKYþ inﬂix 1.5 WKYþ inﬂix 6.0 SHRþveh SHRþ inﬂix 1.5 SHRþ inﬂix 6.0
Heart rate (bpm) 403727.4 389724.3 400726.4 395729.6 394730.1 409728.3
End-diastolic septal wall thickness (mm) 0.128070.026 0.129070.037 0.130070.034 0.154070.004 0.126070.002b 0.138070.008b
End-diastolic posterior wall thickness (mm) 0.138070.004 0.136070.004 0.140070.003 0.166070.004 0.124070.003b 0.142070.002b
Left ventricular end diastolic diamenter (cm) 0.592070.0140 0.694070.0461 0.702070.0454 0.582070.0233 0. 574070.02288 0.596070.0331
Left ventricular end-systolic diamenter (cm) 0.336070.0081 0.320070.0104 0.378070.0376 0.316070.0261 0.314070.0156 0.316070.0261
Left ventricular ejection fraction (%) 8271.8 8271.3 8471.9 8372.1 8372.1 8374.9
Left ventricle mass (mg) 973726.0 977728.4 1078741.1 1051739.8a 909720.4a,b 983727.1a,b
Left ventricle mass index (mg/g) 2.2570.08 2.2470.21 2.0570.16 3.1570.17a 2.9170.06a,b 2.5870.05a,b
Relative wall thickness 0.46770.016 0.43670.022 0.39270.030 0.55270.015a 0.47870.019a,b 0.48170.052a,b
Cardiomyocyte diameter (mm) 17.370.54 18.270.73 17.870.75 32.970.65a 24.870.62a,b 23.170.48a,b
a Po0.01 vs. WKYþveh, WKYþ inﬂix 1.5 and WKYþ inﬂix 6.0.
b Po0.05 vs. SHRþveh.
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Fig. 4. AKT/eNOS activation and inﬂammatory pathways in the left ventricle of WKY and SHR treated with inﬂiximab. The left ventricles were removed from WKY
and SHR treated with vehicle or inﬂiximab for 8 weeks, and samples were prepared for western blot detection of phospho-AKT, AKT, TNFa, phospho-Ikb, Ikb, phospho-JNK
and b-actin (A). Values of phospho-JNK were normalised to b-actin (B). Values of TNFawere normalised to b-actin (C). Values of phospho-Ikb were normalised to total Ikb
(D). Values of phospho-AKT were normalised to total AKT (E). The data are presented as the mean7S.E.M. nPo0.05 vs. WKYþveh; #Po0.05 vs. SHRþveh.
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endogenous ligands that bind to transmembrane receptors with
intrinsic tyrosine kinase activity. Thus, insulin receptor tyrosine
phosphorylation and subsequent tyrosine phosphorylation of
substrates that serve as docking platforms, such as IRS, are the
initial rate-limiting steps for insulin-mediated AKT activation.
Recently, evidence has emerged demonstrating the importance of
IRS serine phosphorylation in blunting insulin-receptor-mediated
IRS tyrosine phosphorylation, which leads to a reduction in insulin-
induced AKT activation and, by extension, insulin resistance
(Taniguchi et al., 2006).
Convincing studies have reported that increased serine phos-
phorylation of IRS is the most reliable mechanism through which
chronic, subclinical inﬂammation causes insulin resistance in
obese animals and humans (Paz et al., 1997). Several circulating
factors can modulate IRS serine phosphorylation in insulin-
sensitive tissues, but TNFa, produced by adipose tissue, plays a
critical role (Kanety et al., 1995). Two serine/threonine kinases
activated by TNFa, c-Jun N-terminal Kinase (JNK) and inhibitor of
NF-kB kinase (IkK), are known to mediate IRS serine phosphor-
ylation and insulin resistance (Taniguchi et al., 2006).
In addition, TNFa was shown to cause insulin resistance and to
reduce eNOS activation in endothelial progenitor cells (Chen et al.,
2011). Importantly, TNFa-induced impairment of eNOS activation
was described to be dependent on IkK and JNK in the arteries of
ob/ob mice (Yang et al., 2009). In concordance with these reports,
we found that inﬂiximab reduced both Ikb and JNK phosphoryla-
tion in the aortas of SHR. Because TNFa expression is positively
regulated by NF-kB activity (Messer et al., 1990), the present
results showing that inﬂiximab decreases TNFa expression in the
aorta of hypertensive rats further corroborates the proposition
that this drug reduces the activity of the IkK/Ikb/NF-kB pathway
in aortic tissue. Furthermore, other anti-hypertensive pharmaco-
logical approaches were described to decrease TNFa expression
and NF-kB activity in the aorta of SHR (Sanz-Rosa et al., 2005).
Interestingly, vehicle-treated SHR had lower levels of TNFa in the
aorta compared to vehicle-treated WKY. Thus, it is possible that
TNFa produced by the adipose tissue acts in the aorta of SHR,
where it contributes to elevated blood pressure. We believe that
the reduction in TNFa that was observed in the aorta of SHR after
inﬂiximab treatment is a consequence of negative regulation of
the NF-kB and JNK pathways due to TNFa neutralisation.
To determine whether the reduction in systolic blood pressure
induced by inﬂiximab correlated with changes in left ventricular
function, we assessed various echocardiographic parameters in
SHR and WKY. Upon comparing these groups, we found no
differences in left ventricular systolic or diastolic function. In
contrast, left ventrivle mass index and cardiomyocyte diameter
were clearly reduced in SHR treated with inﬂiximab. In agreement
with these data, it has been shown that increasing pressure
induced by aortic constriction is able to stimulate left ventricle
hypertrophy, which is attenuated by eNOS activation (Bhuiyan
et al., 2009). Thus, we hypothesise that inﬂiximab-induced
upregulation of the AKT/eNOS pathway in the aorta increases
vascular relaxation and, consequently, reduces pressure overload-
induced ventricle hypertrophy in SHR. Further supporting this
hypothesis, eNOS knockout mice are known to display increased
systolic blood pressure and left ventricle hypertrophy (Yang et al.,
1999).
In contrast to what we observed in the aorta, AKT phosphor-
ylation was decreased in the left ventricle of inﬂiximab-treated
rats. One possible explanation for these differential effects of
inﬂiximab may be that pressure overload is a key stimulator
of AKT activation in the left ventricle that leads to ventricle
hypertrophy (Ha et al., 2005). Therefore, we believe that the
reduction in cardiac AKT activation by inﬂiximab is secondary toupregulation of endothelial AKT/eNOS. This adaptation would
reduce left ventricle hypertrophy in SHR.
Because AKT activation is implicated in the inhibition of
apoptosis, favouring cell survival in many cell types, we assessed
caspase-3 processing in the cardiac tissue of inﬂiximab-treated
rats. We found that inﬂiximab treatment actually reduced caspase-
3 processing in the left ventricle of SHR, which strongly suggests
that this drug does not induce apoptosis in the left ventricle
despite a decrease in AKT phosphorylation.
In summary, our data demonstrate that neutralisation of
circulating TNFa by inﬂiximab reduces systolic blood pressure
in hypertensive rats. This reduction is associated with upregula-
tion of AKT/eNOS in the aorta. In addition, we demonstrate that
upregulation of the AKT/eNOS pathway in the aorta correlates
with reduced arterial TNFa expression and Ikb and JNK activation.
This adaptation most likely results in indirect reduction of left
ventricle hypertrophy and cardiac AKT activation.Acknowledgements
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